Security readout for executives and security teams
Plain-English summary
CVE-2023-37613 is reported as a cross-site scripting issue in Assembly Software Trialworks v11.4. A malicious value in an asset source parameter could cause attacker-controlled script or HTML to run in a user's browser. The public bundle does not provide CVSS scoring, official vendor remediation, or confirmed exploitation.
Executive priority
Track this as a targeted application risk, not a confirmed emergency from the provided evidence. Prioritize faster if Trialworks v11.4 is internet-facing, handles sensitive legal data, or is accessed by privileged users.
Technical view
The CVE describes XSS through crafted input in the asset src parameter of Trialworks v11.4. The available evidence names arbitrary web script or HTML execution, but does not include a CWE, CVSS vector, vendor advisory, patch version, or environmental prerequisites. KEV status is false in the provided bundle.
Likely exposure
Exposure is most relevant where Trialworks v11.4 is deployed and reachable by users through a web interface. The provided affected-product metadata is incomplete, so teams should verify product ownership, version, and whether the vulnerable parameter is accessible in their environment.
Exploitation context
The sources describe the vulnerability class and input location, but do not cite active exploitation. The bundle marks KEV as false. No source in the bundle confirms public weaponization, mass scanning, or exploitation in the wild.
Researcher notes
Evidence is thin: the bundle has CVE records and researcher GitHub references, but no CVSS, CWE, vendor advisory, or patch details. Avoid assuming affected versions beyond Trialworks v11.4 unless vendor documentation confirms them.
Mitigation direction
- Check Assembly Software guidance for confirmed fixes or upgrade paths.
- Inventory any Trialworks deployments and confirm installed versions.
- Restrict external access to affected Trialworks interfaces where feasible.
- Apply vendor-provided patches or configuration changes when available.
- Monitor web logs for suspicious requests targeting asset src parameters.
Validation and detection
- Confirm whether Trialworks v11.4 exists in the environment.
- Identify whether the Trialworks web interface is internet-facing.
- Review vendor or support channels for patch status.
- Use approved scanners or safe testing to check reflected script handling.
- Review logs for unusual asset parameter values.
Public sources used
Generated from the cited source records. This long-tail analysis has not been individually reviewed by a named human.
Conservative CVE-to-ATT&CK context
These mappings and lookup hints may be relevant to the vulnerability behavior, CWE, affected product, or exposure path. Glexia-inferred context is not an official MITRE, ATT&CK, CWE, or CVE Program mapping.
ATT&CK lookup starting points
Use these exact CWE pages and searches to review the Glexia ATT&CK library from this CVE's weakness and description context.
CVE-2023-37613 mapping review
Open the CVE-to-ATT&CK bridge for reviewed, inferred, or future official mappings tied to this CVE.
Open ATT&CK lookup- Severity
- Unknown
- CVSS
- Not scored
- Known Exploited
- No
- Published
CNA and ADP enrichment extracted from CVE v5
These fields come from the CVE record and ADP containers, not from Glexia's Take. They preserve time-varying source decisions such as CISA SSVC, KEV status, CVSS metrics, and provider references.
CVSS and timeline data
No CVSS vectors or timeline events were available in the normalized CVE source material.
Source materials
Products and packages named in the record
CWE details
CWE links open Glexia weakness intelligence pages with official CWE context, developer remediation guidance, and related CVE mappings.